Allurion Technologies (Allurion Technologies) Debt-to-Asset : 0.70 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Debt-to-Asset?

Allurion Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $39.77 Mil. Allurion Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.01 Mil. Allurion Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $59.99 Mil. Allurion Technologies's debt to asset for the quarter that ended in Mar. 2024 was 0.70.

Allurion Technologies Debt-to-Asset Historical Data

The historical data trend for Allurion Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Debt-to-Asset Chart

Allurion Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

0.66

1.16

0.58

Allurion Technologies Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial					1.28	1.48	0.51	0.58	0.70

Competitive Comparison of Allurion Technologies's Debt-to-Asset

For the Medical Devices subindustry, Allurion Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allurion Technologies's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Debt-to-Asset falls into.

Allurion Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Allurion Technologies's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(39.551	+	2.306)	/	71.712
	=	0.58

Allurion Technologies's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(39.771	+	2.011)	/	59.988
	=	0.70

Allurion Technologies (NYSE:ALUR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Allurion Technologies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Allurion Technologies (Allurion Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760